Patents Assigned to Taiwan Biotech Co., Ltd.
-
Patent number: 9308203Abstract: Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection and surrounding skin. A method for the transdermal treatment or prevention of fungal toenails or fingernails or foot infections with an antifungal agent is also disclosed, the method comprising adhesively securing to a dorsal site of an infected palm or foot a pressure-sensitive adhesive matrix patch device for a time sufficient to deliver an effective amount of the antifungal agent to an area of infection.Type: GrantFiled: September 30, 2009Date of Patent: April 12, 2016Assignee: TAIWAN BIOTECH CO., LTD.Inventors: Kuo-Hua Yang, Yung-Jin Lee, Li-Chin Lin
-
Publication number: 20150064129Abstract: The invention discloses a composition comprising hyaluronic acid with a high molecular weight and povidone-iodine in low amount that has advantageous efficacy in enhancing wound healing and maintains high stability. Also disclosed is a method of using the composition of the invention in healing wounds.Type: ApplicationFiled: September 4, 2013Publication date: March 5, 2015Applicant: TAIWAN BIOTECH CO., LTD.Inventors: LiChin Lin, YuKao Cheng, YuHua Chen, ShuFang Chiang
-
Patent number: 8868225Abstract: A web-based tool (as a server) for integrated pharmaceutical analysis and report generation service is provided in the present invention. The server can be used for numerical analysis and report generation for pharmaceutical manufacturing, research and development, and has advantages such as simple operation, complicated but fast calculation and professional report generation, and high accuracy. The server includes at least one pharmaceutical manufacturing and research and development numerical analysis system configured to perform different pharmaceutical manufacturing and research and development numerical analyses and generate different reports.Type: GrantFiled: May 6, 2011Date of Patent: October 21, 2014Assignee: Taiwan Biotech Co., Ltd.Inventors: Yung-Jin Lee, Ching-Feng Wang, Hung-Liang Chen, Ju-Min Chiu
-
Patent number: 8765997Abstract: Provided is a process for preparing 4-borono-L-phenylalanine, which has steps of: reacting N-protected (S)-4-halophenylalanine of formula (I), a boronating agent and an organolithium to obtain a reaction mixture, wherein the reaction mixture comprises N-protected (S)-4-boronophenylalanine of formula (II) and the R group represents a protecting group; isolating the N-protected (S)-4-boronophenylalanine from the reaction mixture; deprotecting the R group of the N-protected (S)-4-boronophenylalanine to obtain L-BPA.Type: GrantFiled: June 5, 2013Date of Patent: July 1, 2014Assignee: Taiwan Biotech Co., Ltd.Inventors: Chia-Cheng Shaw, Kuen-Wang Sheu, Shu-Fen Huang
-
Publication number: 20140052081Abstract: The present invention relates to a donepezil transdermal patch comprising a backing layer and a pressure sensitive adhesive matrix layer, wherein the pressure sensitive adhesive matrix layer comprises donepezil free base and an acrylic pressure sensitive adhesive agent selected from the group consisting of a copolymer of 2-ethylhexyl acrylate and vinyl acetate and a copolymer of 2-ethylhexyl acrylate, vinyl acetate, and hydroxyl-containing monomers, and wherein 2-ethylhexyl acrylate is present in an amount of about 65% to about 75%, vinyl acetate is present in an amount of about 25% to about 35%, and the hydroxyl-containing monomers are in an amount of about 0% to about 10%, based on the total weight of the copolymer.Type: ApplicationFiled: January 12, 2012Publication date: February 20, 2014Applicant: TAIWAN BIOTECH CO. LTD.Inventors: Kuo-Hua Yang, Chih-Sheng Yang, Hsuen-Yau Lin
-
Patent number: 8641900Abstract: A method and a device for continuously preparing microspheres, and a collection unit thereof are provided. The collection unit for collecting microspheres in the solution comprises a tank and a first plate. The first plate is removably disposed in the tank. The first plate, when lay across the tank, has its two ends came in contact with the sidewall of the tank so as to divide the tank into a first chamber and a second chamber. The tank has an outlet located in the second chamber. After the solution with microspheres are input to the first chamber of the tank, the microspheres are deposited around the first plate, and the solution is caused to pass through or over the first plate to the second chamber and output from the outlet.Type: GrantFiled: November 4, 2010Date of Patent: February 4, 2014Assignee: Taiwan Biotech Co., LtdInventors: Shou-Min Huang, Chun-Wei Liu, Kuo-Hua Yang
-
Patent number: 8552195Abstract: The method in accordance with the present invention has: mixing E2M, an organic solvent, a weak base, sodium dithionite, and a phase transfer catalyst to obtain an E2M mixture solution; heating the E2M mixture solution and adding water to obtain a heated E2M aqueous solution having an organic layer; and extracting the organic layer from the heated E2M aqueous solution, and condensing and drying the organic layer to obtain donepezil. Employing sodium dithionite as a reducing agent improves safety over hydrogen gas used in conventional methods and lowers the cost in contrast to the conventional noble metal catalysts that are extremely expensive. Furthermore, the method of the present invention requires only 60 minutes of reaction time to synthesize donepezil with a promising yield more than 85%, which greatly raises the efficiency and economic value of the manufacture of donepezil.Type: GrantFiled: August 5, 2011Date of Patent: October 8, 2013Assignee: Taiwan Biotech Co., Ltd.Inventors: Kuen-Wang Sheu, Shu-Fen Huang
-
Patent number: 8470365Abstract: This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.Type: GrantFiled: July 29, 2010Date of Patent: June 25, 2013Assignee: Taiwan Biotech Co., Ltd.Inventors: Li-Heng Pao, Nion-Heng Shiao, Kuo-Hua Yang, Jui-Ming Chou
-
Publication number: 20130078304Abstract: The invention relates to a controlled-release formulation for preventing and/or treating sleep disorders comprising Zaleplon or a pharmaceutically acceptable salt thereof in immediate release form and Zolpidem or a pharmaceutically acceptable salt thereof in sustained release form, wherein Zaleplon or a pharmaceutically acceptable salt thereof and Zolpidem or a pharmaceutically acceptable salt thereof are released in two phases where the first phase is a immediate release phase of Zaleplon or a pharmaceutically acceptable salt thereof and the second phase is a sustained release phase of Zolpidem or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 28, 2011Publication date: March 28, 2013Applicant: TAIWAN BIOTECH CO., LTD.Inventors: HSIEN-JEN HSIEH, KUO-HUA YANG, CHIH-SHENG YANG, YU-CHENG WEI, CHUNG-HSUAN LU
-
Publication number: 20130035490Abstract: The method in accordance with the present invention has: mixing E2M, an organic solvent, a weak base, sodium dithionite, and a phase transfer catalyst to obtain an E2M mixture solution; heating the E2M mixture solution and adding water to obtain a heated E2M aqueous solution having an organic layer; and extracting the organic layer from the heated E2M aqueous solution, and condensing and drying the organic layer to obtain donepezil. Employing sodium dithionite as a reducing agent improves safety over hydrogen gas used in conventional methods and lowers the cost in contrast to the conventional noble metal catalysts that are extremely expensive. Furthermore, the method of the present invention requires only 60 minutes of reaction time to synthesize donepezil with a promising yield more than 85%, which greatly raises the efficiency and economic value of the manufacture of donepezil.Type: ApplicationFiled: August 5, 2011Publication date: February 7, 2013Applicant: Taiwan Biotech Co, Ltd.Inventors: Kuen-Wang Sheu, Shu-Fen Huang
-
Publication number: 20120027853Abstract: This invention relates to a process for preparing a pharmaceutical composition comprising four antitubercular drugs: rifampin or a pharmaceutically acceptable salt thereof, isoniazid or a pharmaceutically acceptable salt thereof, pyrazinamide or a pharmaceutically acceptable salt thereof and ethambutol or a pharmaceutically acceptable salt thereof, wherein rifampin and isoniazid are in separate layers. The invention also provides a pharmaceutical composition prepared therefrom having advantageous stability and bioavailability.Type: ApplicationFiled: July 29, 2010Publication date: February 2, 2012Applicants: Taiwan Biotech Co., Ltd.Inventors: Li-Heng Pao, Nion-Heng Shiao, Kuo-Hua Yang, Jui-Ming Chou
-
Publication number: 20110276161Abstract: A web-based tool (as a server) for integrated pharmaceutical analysis and report generation service is provided in the present invention. The server can be used for numerical analysis and report generation for pharmaceutical manufacturing, research and development, and has advantages such as simple operation, complicated but fast calculation and professional report generation, and high accuracy. The server includes at least one pharmaceutical manufacturing and research and development numerical analysis system configured to perform different pharmaceutical manufacturing and research and development numerical analyses and generate different reports.Type: ApplicationFiled: May 6, 2011Publication date: November 10, 2011Applicant: TAIWAN BIOTECH CO., LTD.Inventors: Yung-Jin Lee, Ching-Feng Wang, Hung-Liang Chen, Ju-Min Chiu
-
Publication number: 20110101553Abstract: A method and a device for continuously preparing microspheres, and a collection unit thereof are provided. The collection unit for collecting microspheres in the solution comprises a tank and a first plate. The first plate is removably disposed in the tank. The first plate, when lay across the tank, has its two ends came in contact with the sidewall of the tank so as to divide the tank into a first chamber and a second chamber. The tank has an outlet located in the second chamber. After the solution with microspheres are input to the first chamber of the tank, the microspheres are deposited around the first plate, and the solution is caused to pass through or over the first plate to the second chamber and output from the outlet.Type: ApplicationFiled: November 4, 2010Publication date: May 5, 2011Applicant: TAIWAN BIOTECH CO., LTD.Inventors: Shou-Min HUANG, Chun-Wei Liu, Kuo-Hua Yang
-
Publication number: 20100081669Abstract: Disclosed is a pressure-sensitive adhesive matrix patch device for treatment or prevention of fungal toenails or fingernails or foot infections comprising an antifungal agent or two or more antifungals in combination and adhesively secured to a dorsal site of an infected palm or foot, rather than an area of infection and surrounding skin. A method for the transdermal treatment or prevention of fungal toenails or fingernails or foot infections with an antifungal agent is also disclosed, the method comprising adhesively securing to a dorsal site of an infected palm or foot a pressure-sensitive adhesive matrix patch device for a time sufficient to deliver an effective amount of the antifungal agent to an area of infection.Type: ApplicationFiled: September 30, 2009Publication date: April 1, 2010Applicant: Taiwan Biotech Co., Ltd.Inventors: Kuo-Hua Yang, Yung-Jin Lee, Li-Chin Lin
-
Publication number: 20090186087Abstract: An enteric sustained-release coated core includes a drug-containing core and a coating film. The coating film includes 20%˜80% by weight of a hydrophobic polymer and 10%˜70% by weight of an enterosoluble material. The dissolution rate of the medical component in the drug-containing core is approximately less than 10% in hydrochloric acid solution of pH 1˜3 after 2 hours. The dissolution of the medical component in the drug-containing core sustains more than 5 hours in phosphate buffer solution of pH 5˜8.Type: ApplicationFiled: January 21, 2009Publication date: July 23, 2009Applicant: TAIWAN BIOTECH CO., LTD.Inventors: Min-Chuan HSU, Yu-Kao CHENG, Li-Chin LIN
-
Patent number: 7282606Abstract: The present invention discloses a new process for the synthesis of tamsulosin and its aralkylamine derivatives, especially (R)-(?)-5-{2-[2-(2-alkoxyphenoxy) ethylamino]propyl}-2-alkoxybenzenesulfonamides having the following formula 1 (where R1 and R2 represent C1-C4 alkyl groups) and their hydrochloride thereof, and other various pharmaceutical used salts. Tamsulosin hydrochloride (R1=Et, R2=Me, in its hydrochloride salt form) is an antagonist of ?-A adrenoceptors in the prostate. Tamsulosin•HCl occurs as white crystals, which melt with decomposition at approximately 230° C. It is sparingly soluble in water and in methanol, slightly soluble in glacial acetic acid and in ethanol, and practically insoluble in ether.Type: GrantFiled: July 13, 2005Date of Patent: October 16, 2007Assignees: Well-Being Biochemical Corp., Taiwan Biotech Co., Ltd.Inventors: Ru Hwu Jih, Shwu Chen Tsay, Balaachary Magendran, Subhasish K. Chakraborty, Asish R. Das, Kuen Wang Sheu, Chun Mei Shu, Chin Kun Lu, Wei Min Chang